8 recruiting, 1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow HER2-low Breast Cancer: new trials by email Literature Review of HER2-low Breast Cancer trials Research Report on HER2-low Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors CGT6297 - PIK3CA Mutations, Advanced Solid Tumors, Adult | Phase 1 | Recruiting | Cogent Biosciences, Inc. | 90 | 2026-07-23 | 2026-10-22 |
| HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC Positron emission tomografy with [68Ga]Ga-ABY-025 - Breast Cancer Stage IV, HER2-low Breast Cancer | Recruiting | Renske Altena | 70 | 2025-10-03 | 2025-11-20 | |
| Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer Trastuzumab-rezetecan Treatment Group - Trastuzumab-rezetecan, HER2-low Breast Cancer | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 300 | 2025-06-01 | 2026-01-22 | |
| A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel - HER2-low Breast Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 566 | 2025-05-15 | 2026-01-21 |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd Trastuzumab Deruxtecan, Datopotamab Deruxtecan - Breast Cancer, HER2-low Breast Cancer | Phase 2 | Recruiting | Ana C Garrido-Castro, MD | 357 | 2024-10-29 | 2026-08-26 |
| A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) Trastuzumab deruxtecan - HER2-positive Breast Cancer, HER2-low Breast Cancer | Recruiting | Daiichi Sankyo | 800 | 2024-01-15 | 2026-01-12 | |
| Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study Disitamab Vedotin (RC48), Bevacizumab - HER2-low Breast Cancer | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 37 | 2024-01-01 | 2026-03-03 |
| Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer No drug - Hormone-receptor-positive Breast Cancer, HER2-low Breast Cancer | Completed | Daiichi Sankyo | 927 | 2023-07-31 | 2024-02-26 | |
| Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer Standard Management - Breast Cancer, HER2-low Breast Cancer | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 255 | 2022-08-07 | 2026-10-19 | |
| Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer Non-intervention research - Antibody-drug Conjugates, HER2-low Breast Cancer | Recruiting | Sun Yat-sen University | 700 | 2020-01-01 | 2025-03-20 |
Breast Neoplasms (6) · Endometrial Neoplasms (1)
Breast Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
trastuzumab deruxtecan (2) · Bevacizumab (1) · Capecitabine (1) · Gemcitabine (1) · Paclitaxel (1) · RC48 antibody (1) · disitamab vedotin (1) · eribulin (1)
Daiichi Sankyo (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Ana C Garrido-Castro, MD (1) · Cogent Biosciences, Inc. (1) · Renske Altena (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1) · Sun Yat-sen University (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (6) · United States (3) · Sweden (1)
Ana Garrido-Castro, MD (1) · Gong Chang, doctor (1) · Renske Altena, MD PhD (1)